Ozone, Motohiro
Hirota, Susumu
Ariyoshi, Yu
Hayashida, Kenichi
Ikegami, Azusa
Habukawa, Mitsunari
Ohshima, Hayato
Harada, Daisuke
Hiejima, Hiroshi
Kotorii, Nozomu
Murotani, Kenta
Taninaga, Takehiro
Uchimura, Naohisa
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study
https://doi.org/10.1007/s12325-024-02811-2
Funding for this research was provided by:
Eisai Co., Ltd.
Article History
Received: 21 August 2023
Accepted: 2 February 2024
First Online: 9 March 2024
Declarations
:
: Motohiro Ozone received grants from Mitsubishi Tanabe Pharma Corporation, Tsumura Co., Ltd., Shionogi & Co., Ltd., Mochida Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Teijin Pharma Ltd.; and honoraria from Eisai Co., Ltd., Tsumura Co., Ltd., MSD Co., Ltd., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nobelpharma Co., Ltd., Yoshitomi Pharmaceutical Industries, Ltd., and Mitsubishi Tanabe Pharma Corporation. Susumu Hirota received consulting fees from Viatris Inc.; honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., Sumitomo Pharma Co., Ltd., and Takeda Pharmaceutical Company Ltd.; and is involved in clinical trials with Nippon Boehringer Ingelheim Co., Ltd., Shiongi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Viatris Inc. Yu Ariyoshi received honoraria from Eisai Co., Ltd. and MSD Co., Ltd. Kenichi Hayashida received lecture fees from Eisai Co., Ltd. and MSD Co., Ltd. Azusa Ikegami received honoraria from Eisai Co., Ltd. Mitsunari Habukawa received honoraria from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD Co., Ltd., and Takeda Pharma Co., Ltd., Nozomu Kotorii received consulting fees from Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, MSD Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Janssen Pharmaceutical K.K. Takehiro Taninaga is an employee of Eisai Co., Ltd. Naohisa Uchimura received honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD Co., Ltd., Nobelpharma Co., Ltd., and Takeda Pharmaceutical Company Limited. The remaining authors have no conflicts of interest to declare.
: The study protocol was approved by the NPO Clinical Research Network Fukuoka Certified Review Board and was registered at ClinicalTrials.gov under the identifier NCT04742699. The study adhered to the Declaration of Helsinki of 1964 and its later amendments, the Clinical Trials Act (Japanese law), and local regulations. All patients provided informed consent to participate in this study.